M.D., Chief Scientific Officer, CRISPR Therapeutics
Dr Bill Lundberg has extensive experience across all aspects and phases of drug development in both academic and industry settings. He was previously vice president and head of translational medicine at Alexion Pharmaceuticals, where he oversaw the progression of numerous compounds from early research to clinical proof-of-concept. Before that, Bill held senior positions at Taligen Therapeutics, Antisoma, Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme, overseeing the development of diverse portfolios. Bill received his BS in biology from the Massachusetts Institute of Technology, MD from Stanford Medical School and MBA from the University of Massachusetts Amherst. As a post-doctoral fellow, he studied at the Whitehead Institute at MIT and trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Presentation Title and Company Description
Emerging Therapeutics Showcase: Bringing CRISPR Therapeutics Into The Clinic
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas.